Home
ADAP
ADAP News

Latest Adaptimmune Therapeutics plc (ADAP) News on January 19, 2025

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Newsfile

6 days ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

MT Newswires

a month ago

Adaptimmune Therapeutics Chief Financial Officer Gavin Wood to Resign in May 2025

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Newsfile

a month ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Newsfile

2 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

MT Newswires

2 months ago

Mizuho Cuts Price Target on Adaptimmune Therapeutics to $1.50 From $3, Keeps Outperform Rating

Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

2 months ago

Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Halozyme bids for Evotec; BeiGene gets a new name

BioPharma Dive

2 months ago

Halozyme bids for Evotec; BeiGene gets a new name

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints

Pharmaceutical Technology

2 months ago

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints

Zacks Small Cap Research

2 months ago

ADAP 3Q24 Earnings Review: Streamlining the Platform; Profitability Inflection Point in 2027

Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...

GuruFocus.com

2 months ago

Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...

Adaptimmune Reports Q3 2024 Financial and Business Updates

Newsfile

2 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Newsfile

2 months ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Newsfile

2 months ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Newsfile

3 months ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Zacks Small Cap Research

3 months ago

OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions

Simply Wall St.

4 months ago

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

GlobeNewswire

4 months ago

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

GlobeNewswire

4 months ago

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Adaptimmune to Participate in Two Bank Conferences this September

Newsfile

5 months ago

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago

Simply Wall St.

5 months ago

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago

Zacks Small Cap Research

5 months ago

ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload

Adaptimmune Reports Q2 2024 Financial and Business Updates

Newsfile

5 months ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

Pharmaceutical Technology

5 months ago

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

Newsfile

5 months ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma

Pharmaceutical Technology

6 months ago

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma

MT Newswires

6 months ago

Agilent Technologies' MAGE-A4 Test Approved by FDA for Use With T-Cell Receptor Therapy

MT Newswires

6 months ago

Sector Update: Health Care Stocks Decline Premarket Friday

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

Benzinga

6 months ago

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer

BioPharma Dive

6 months ago

First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer

MT Newswires

6 months ago

Adaptimmune Therapeutics Gets Accelerated Approval of Tecelra From FDA

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Business Wire

6 months ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

MT Newswires

6 months ago

HC Wainwright Starts Adaptimmune Therapeutics With Buy Rating, $4 Price Target

Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?

Insider Monkey

6 months ago

Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?

5 FDA decisions to watch in the third quarter

BioPharma Dive

7 months ago

5 FDA decisions to watch in the third quarter

Zacks Small Cap Research

7 months ago

Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Zacks Small Cap Research

7 months ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

7 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

7 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

7 months ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

7 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

7 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

7 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

7 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

7 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

7 months ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

7 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

7 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

7 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

7 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

7 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

7 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

7 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Newsfile

8 months ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

MT Newswires

8 months ago

Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Newsfile

8 months ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

MT Newswires

8 months ago

Scotiabank Starts Adaptimmune Therapeutics With Sector Outperform Rating

MT Newswires

8 months ago

Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating

MT Newswires

8 months ago

Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital

Adaptimmune Reports Q1 2024 Financial and Business Updates

Newsfile

8 months ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Newsfile

8 months ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Newsfile

9 months ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune (ADAP) Down on End of Collaboration With Roche

Zacks

9 months ago

Adaptimmune (ADAP) Down on End of Collaboration With Roche

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Newsfile

9 months ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Roche, Adaptimmune part ways on cell therapy research

BioPharma Dive

9 months ago

Roche, Adaptimmune part ways on cell therapy research

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Newsfile

10 months ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

10 months ago

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

GuruFocus.com

10 months ago

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Newsfile

10 months ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Newsfile

a year ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Newsfile

a year ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

15 Top Performing European Stocks So Far in 2024

Insider Monkey

a year ago

15 Top Performing European Stocks So Far in 2024

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

Zacks

a year ago

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Newsfile

a year ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC

GuruFocus.com

a year ago

Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC

With 30% stake, 1stdibs.Com, Inc. (NASDAQ:DIBS) seems to have captured institutional investors' interest

Simply Wall St.

a year ago

With 30% stake, 1stdibs.Com, Inc. (NASDAQ:DIBS) seems to have captured institutional investors' interest

First Mid Bancshares Full Year 2023 Earnings: EPS Misses Expectations

Simply Wall St.

a year ago

First Mid Bancshares Full Year 2023 Earnings: EPS Misses Expectations

RBB Bancorp (NASDAQ:RBB) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

RBB Bancorp (NASDAQ:RBB) Q4 2023 Earnings Call Transcript

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

Simply Wall St.

a year ago

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

Why WW International Stock Bounced 6% Higher Today

Motley Fool

a year ago

Why WW International Stock Bounced 6% Higher Today

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

PR Newswire

a year ago

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

Dakota Gold Intersects Multiple High-Grade Zones with Visible Gold Mineralization, Including 4.871 oz/ton Au over 3.4 ft (167.0 g/t over 1.0 m), 1200 feet South of the JB Gold Zone on Its Maitland Gold Project

Newsfile

a year ago

Dakota Gold Intersects Multiple High-Grade Zones with Visible Gold Mineralization, Including 4.871 oz/ton Au over 3.4 ft (167.0 g/t over 1.0 m), 1200 feet South of the JB Gold Zone on Its Maitland Gold Project

Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%

Simply Wall St.

a year ago

Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

Zacks

a year ago

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

Insider Sell: Solid Power Inc CTO Joshua Buettner-garrett Sells 187,500 Shares

GuruFocus.com

a year ago

Insider Sell: Solid Power Inc CTO Joshua Buettner-garrett Sells 187,500 Shares

Smartfren Telecom and Aviat Establish Strategic Collaboration in Indonesia

PR Newswire

a year ago

Smartfren Telecom and Aviat Establish Strategic Collaboration in Indonesia

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire

a year ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

The Zacks Analyst Blog Highlights VirTra, REX American Resources, Universal Stainless & Alloy Products, Runway Growth Finance and Carrols Restaurant Group

Zacks

a year ago

The Zacks Analyst Blog Highlights VirTra, REX American Resources, Universal Stainless & Alloy Products, Runway Growth Finance and Carrols Restaurant Group

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Newsfile

a year ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Camden National Corporation to Announce Quarter and Year Ended December 31, 2023 Financial Results on January 30, 2024

PR Newswire

a year ago

Camden National Corporation to Announce Quarter and Year Ended December 31, 2023 Financial Results on January 30, 2024

Red River Bancshares (NASDAQ:RRBI) Ticks All The Boxes When It Comes To Earnings Growth

Simply Wall St.

a year ago

Red River Bancshares (NASDAQ:RRBI) Ticks All The Boxes When It Comes To Earnings Growth

Here's Why We Think Tootsie Roll Industries (NYSE:TR) Might Deserve Your Attention Today

Simply Wall St.

a year ago

Here's Why We Think Tootsie Roll Industries (NYSE:TR) Might Deserve Your Attention Today

NaaS Technology Inc. Announces Amendment of Share Incentive Plan

PR Newswire

a year ago

NaaS Technology Inc. Announces Amendment of Share Incentive Plan

Will Gambling.com (GAMB) be a Strong Long-Term Compounder?

Insider Monkey

a year ago

Will Gambling.com (GAMB) be a Strong Long-Term Compounder?

Calamos Investments Closed-End Funds (NASDAQ: CHI, CHY, CSQ, CGO, CHW, CCD and CPZ) Announce Monthly Distributions and Required Notifications of Sources of Distribution

PR Newswire

a year ago

Calamos Investments Closed-End Funds (NASDAQ: CHI, CHY, CSQ, CGO, CHW, CCD and CPZ) Announce Monthly Distributions and Required Notifications of Sources of Distribution

Investors Don't See Light At End Of American Well Corporation's (NYSE:AMWL) Tunnel

Simply Wall St.

a year ago

Investors Don't See Light At End Of American Well Corporation's (NYSE:AMWL) Tunnel

Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year

Simply Wall St.

a year ago

Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Newsfile

a year ago

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

Zacks

a year ago

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

Zacks

a year ago

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

Share on Social Networks: